Key Takeaways
- Revenue surged 49% YoY, but Q4 margin dip was a scheduling blip: Consolidated revenue hit ₹1,601 crores, driven by 5 new product launches and Tanfac. Standalone EBITDA margin fell ~400 bps QoQ on product mix, which management calls temporary and expects to normalize.
- Order book swelled to ₹5,500 crores with three new fluorination LOIs: All three LOIs are with new customers for first-time-in-India molecules, adding multi-year visibility. The cumulative LOI book now spans 5 to 7 years of supply.
- Fluorine is the strategic growth wedge, targeting 20-25% of revenue: Currently 15% of the portfolio, the fluorine business is set to expand as new LOIs ramp up, with a stated target of 20% by FY24 and 30% by FY27.
- Working capital discipline is improving, with inventory days down to 250: Management is pushing to bring inventory days below the FY21 level of 222, though the role of single-supplier buffer stock may limit how low it can go.
- What to watch next quarter: The pace of commercialization for the 2 new LOI molecules expected in FY24, the trajectory of inventory days toward the sub-200 target, and whether the Q4 margin dip reverses as promised.
Revenue Growth & Product Engine
- Five new products commercialized in FY23, most manufactured in India for the first time, alongside steady organic portfolio growth and the Tanfac contribution.
- Over 10 product launches targeted for FY24, spanning niche pharma and other segments, supported by an R&D team expanding from 88 to a planned 175 scientists.
- Four molecules from earlier LOIs already commercialized, generating around ₹100 crores in revenue, with expansion expected in FY24 and FY25.
- No agro slowdown visible: Management reports that in a few cases, volume expectations from agro customers have actually increased, and revenue projections remain intact.
- Revenue mix shift is gradual: The contribution from pharma and polymers will rise while agro's share dips slightly, but agro continues to grow in absolute terms.
Anand Desai: "This growth was driven by 3 important factors. The first factor was commercialization of 5 new products during the year; second thing is steady growth of our organic product portfolio and third was strong performance by Tanfac."
Order Book & New LOI Wins
- Three new LOIs signed, all fluorination-based and with new customers: The LOIs are valued at ₹1,500 crores (7 years), ₹980 crores, and ₹380 crores, bringing the cumulative LOI book to ₹5,500 crores.
- First-time-in-India molecules: These products are currently manufactured by the customers themselves or sourced from Europe and other geographies, not from India, giving Anupam a pioneer position.
- At least 2 molecules from the new LOIs expected to commercialize in FY24, with the balance in FY25 and full ramp-up by FY26 or two years thereafter.
- No major capex needed for the new LOIs: The existing fluorination block should be able to service the new contracts, with only small amendments required at Tanfac.
- LOI-to-revenue conversion is high-visibility: Once an LOI is in place, revenue visibility is very high unless a significant error is made, though management declined to provide specific FY26/FY27 revenue numbers from these LOIs.
- Customer stickiness is structural: After contract expiry, customers rarely move away because of the process optimization, supply chain creation, and value engineering built up over the contract period.
Vishal Thakkar: "These are the products which are typically manufactured by customer existing today or maybe sourcing from Europe and other geographies. These are the products which are not being manufactured or sourced from India."
Fluorination Strategy
- Fluorine-based business is currently ~15% of the portfolio, with a target to reach 20% by FY24 and 30% by FY27, allowing for a couple of percentage points of variance.
- New LOI chemistries are predominantly HF-side rather than KF-side, though management did not specify the exact chemistries involved.
- Tanfac acquisition builds on the existing fluorination portfolio, with Tanfac providing one-step processing capacity that Anupam will support with required additional steps.
- Europe-plus-one trend is structural and continuing: Even as European energy prices rationalize, customers are introducing Asian players earlier in the product life cycle for business continuity planning reasons.
Vishal Thakkar: "Once they have seen that shockwave, they really believe that they have to finally alternate and they have to do, as there are various words for that like BCP and other, but they would do that."
Margins & Profitability
- Standalone EBITDA margin dipped ~400 bps QoQ due to product mix changes and a couple of products with lower gross margins, which management attributes to scheduling and expects to revert to normal levels.
- EBITDA margin guidance is 26% to 28%, with management acknowledging the possibility of higher margins but anchoring expectations at that range.
- New LOI molecules carry higher ASPs, creating room for better margins through a two-way play of value-added pricing and process efficiency.
- Pricing on new orders is largely on a 6-month basis, with an option to reprice every six months, providing some insulation against raw material volatility.
Vishal Thakkar: "It's just the scheduling and the product mix that we would see."
Balance Sheet & Capital Allocation
- Inventory days reduced from 291 in FY22 to 250 in FY23, with a target to go below the FY21 level of 222 days, though management deferred committing to a specific number below that.
- Cash flow from operations reached ₹244 crores, driven by strong revenue growth, stable margins, and a better working capital cycle, with management confident of continued robust cash generation.
- FY24 capex guided at ₹350-400 crores, with new capex expected to deliver asset turnover of over 1.75x, a significant improvement.
- ₹670 crores budgeted for three brownfield projects to service LOI requirements, ensuring capacity for the next 3 to 5 years of growth.
- Tanfac will fund its own capex independently from its balance sheet; the ₹670 crores is for Anupam's standalone capacity and requirements.
- Inorganic growth remains on the radar, with management evaluating multiple strategic opportunities across geographies but pledging to remain cautious and selective, acquiring only if strategic and value-accretive.
Kiran Patel: "I can assure all of our shareholders that we will continue to be cautious and selective in evaluation of these opportunities. And like the acquisition of Tanfac, we will acquire companies only if they are strategic and value accretive to Anupam."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Robust growth on a standalone basis, consistent with historical trajectory | Next 3 to 5 years |
| Product launches | Over 10 new products across segments including niche pharma | FY24 |
| New LOI commercialization | At least 2 molecules from the new fluorination LOIs | FY24 |
| New LOI full ramp-up | Balance of molecules from new LOIs fully ramped | FY26 or 2 years thereafter |
| EBITDA margin | 26% to 28% | Ongoing |
| Fluorine revenue share | 20% of portfolio | FY24 |
| Fluorine revenue share | 30% of portfolio | FY27 |
| Inventory days | Below FY21 level of 222 days | FY24 |
| Capex | ₹350 to 400 crores | FY24 |
| Brownfield capex | ₹670 crores for 3 projects to service LOI requirements | Over next 3 to 5 years |
| R&D team size | 175 scientists | FY24 |
| Asset turnover on new capex | Over 1.75x | On new capex |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Consolidated operating revenue | ₹480 crore, up 48% YoY |
| Standalone operating revenue | ₹1,284 crore, up 20% YoY |
| Consolidated EBITDA | ₹141.6 crore, up 46% YoY; margin at 28% |
| Consolidated EBITDA margin (standalone, excl. other income) | Declined ~400 bps QoQ (per an analyst's math) |
| Consolidated profit after tax | ₹72.6 crore, up 58% YoY |
| Full-year consolidated operating revenue | ₹1,601.9 crore, up 49% YoY |
| Full-year consolidated EBITDA | ₹439.9 crore, up 41% YoY; margin at 27% |
| Full-year consolidated profit after tax | ₹216.8 crore, up 42% YoY |
| Cash flow from operations | ₹244 crore generated during the year |
| Cash on books | ₹551 crore as of March 31, 2023 |
| Capex incurred | ₹177 crore during FY23 |
| Capex guidance | ₹350 crore to ₹400 crore for FY24 |
| Budgeted capex for 3 brownfield projects | ₹670 crore total, to be spent over FY24–FY25 |
| Cumulative LOIs and contracts | ₹5,500 crore, to be supplied over 5 to 7 years |
| Inventory days | 250 days, improved from 291 days in FY22 |
| Fluorine-based business contribution | ~15% of portfolio currently; expected to reach 20%–25% in 2–3 years |
| R&D team size | 88 professionals, grew by 11 scientists in FY23 |
| Products commercialized | 5 new products during FY23; target of over 10 in FY24 |
| Revenue from earlier LOIs commercialized | ~₹100 crore from 4 molecules commercialized |
| Top 10 customer concentration | 82% of total revenue, across 24 products |
| Export share | 64% of revenue |
| Solar power capacity | 17.9 MW installed, expected savings of ₹14 crore per annum |